SCHEMBL324577

SCHEMBL324577

Cc1csc(COC(=O)N2C=Cc3ccccc3C2)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.35
NAMPT P43490 1/20 0.35
ADAMTS5 Q9UNA0 1/20 0.34
NPC1 O15118 4/20 0.34
MAPT P10636 3/20 0.34
PARP1 P09874 1/20 0.34
L3MBTL1 Q9Y468 4/20 0.33
HDAC3 O15379 1/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
MAPK1 P28482 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324968 0.83 ALDH1A1 (0.44) RAB9ANAMPTNPC1MAPTL3MBTL1
SCHEMBL324887 0.83 CYP3A4 (0.36) HDAC3GRM5ALDH1A1SMN1; SMN2
SCHEMBL323970 0.81 SMN1; SMN2 (0.34) RAB9ANPC1HDAC3GABRA1GABRG2
SCHEMBL15056293 0.81 DPP4 (0.41) HDAC3GABRA1GABRG2GABRB3GABRA5
SCHEMBL29493251 0.80 HDAC3 (0.41) RAB9ANAMPTMAPTL3MBTL1HDAC3
SCHEMBL15056964 0.80 HDAC3 (0.41) RAB9ANAMPTMAPTL3MBTL1HDAC3
SCHEMBL325217 0.80 HDAC3 (0.33) HDAC3GRM5
SCHEMBL324266 0.79 CYP1A2 (0.53) RAB9ANPC1MAPTL3MBTL1MAPK1
SCHEMBL324346 0.79 P2RX4 (0.47) RAB9ANPC1MAPTL3MBTL1TDP1
SCHEMBL324798 0.78 GRIN2B (0.40) RAB9ANPC1MAPTHDAC3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575158-B2 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2013-11-05 US disclosed
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 RAB9A 1846/4885NAMPT 2828/4885ADAMTS5 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.